lilly_building_with_american_flag_web

Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials

pharmafile | February 5, 2019 | News story | Manufacturing and Production, Research and Development |  Eli Lilly, Olumiant, atopic dermatitis, pharma 

Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). The company and its partner Incyte announced that the drug had met its primary endpoint as a monotherapy in the treatment of adult patients with moderate to severe atopic dermatitis (AD).

Specifically, the pair revealed that a “statistically significant” proportion of patients treated with the therapy achieved clear or almost clear skin after 16 weeks compared to placebo, as measured according to the Investigator’s Global Assessment for AD (IGA). The therapy’s safety profile was found to be similar to placebo.

The two studies which generated these data are to be accompanied by three others as part of a five-part programme to support global regulatory submissions of the therapy. Full results of the two studies are due to appear at upcoming scientific meetings and in peer-reviewed journals.

“Atopic dermatitis is a chronic inflammatory skin disease that can negatively impact the quality of life for patients, and unfortunately there are limited treatment options, particularly oral medications,” commented Dr Lotus Mallbris, Vice President of Immunology Development at Eli Lilly. “We are encouraged that baricitinib met the primary endpoints in these two studies, and look forward to seeing the collective results of all five studies.”

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

The Gateway to Local Adoption Series

Latest content